Arabic Labelling and IFU: Hard Requirements and Common Errors of Bilingual Compliance

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Subparagraph (g) of Article 6(1) makes labelling and the package insert a standalone condition for obtaining the marketing authorization: the inner and outer packaging and the paper or electronic insert must provide the full product information and comply with the EDE labelling guidance. This is not a formality; it is a substantive threshold that can directly cause rejection. Our conclusion is that bilingual labelling should be verified with the Arabic text as the object of review and the Chinese or English text as the reference, because when the product circulates within the UAE, the Arabic text is the text on which regulators and users actually rely.

  • Article 6(1)(g) makes complete packaging and insert information an independent condition for authorization.
  • Labelling failures are a substantive rejection ground, not a formality.
  • The Arabic text is the object of review; the Chinese or English text serves only as the comparison.
  • The Federal Law No. 8 of 2019 has been repealed and the EDE labelling guidance now governs.
  • One master label text should serve registration, customs clearance, and advertising approval alike.
  • Electronic inserts are acceptable provided the access path is stated on the label.
  • Articles 44 to 47 require advertising approval by EDE, and Article 46 allows the applicant to choose a validity period of 30 days to 1 year.
  • Because the same wording is reused at three stages, a single master label text keeps registration, clearance, and advertising aligned.
  • Any modification starts from the master text and is synchronized outward to all three stages.

2. Legal basis

The regulatory basis combines subparagraph (g) of Article 6(1) of Federal Decree-Law No. 38 of 2024 with the prohibition provisions and the institutional mandate that govern labelling. The table below reproduces the instruments cited in the source material and their key points.

UAE Federal Decree-Law on the Regulation of Medical Products, Pharmacists and Pharmaceutical EstablishmentsFederal Decree-Law No. 38 of 2024Published in the Official Gazette on 2024-10-14; entered into force on 2025-01-02Article 6(1)(g)Inner and outer packaging and paper or electronic package inserts must provide the full product information and comply with the EDE labelling guidance
UAE Federal Decree-Law on the Regulation of Medical Products, Pharmacists and Pharmaceutical EstablishmentsFederal Decree-Law No. 38 of 2024Published in the Official Gazette on 2024-10-14; entered into force on 2025-01-02Article 39Counterfeit, defective, and expired products are prohibited; inaccurate label information can fall within the scope of this article
UAE Federal Decree-Law on the Establishment of the Emirates Drug EstablishmentFederal Decree-Law No. 28 of 20232023 (cabinet approval of the establishment reported on 2023-10-30 by the Emirates News Agency)Institutional mandate provisionsEDE took over labelling guidance development and related services; labelling requirements within the country uniformly follow what EDE publishes

3. Expert insights

Insight 1: The issuing body of the labelling guidance has changed with the institutional transition. Federal Law No. 8 of 2019 has been repealed by Federal Decree-Law No. 38 of 2024, and the EDE, established under Federal Decree-Law No. 28 of 2023, took over the registration, classification, pricing, and vigilance services previously performed by MOHAP. Our judgment is that any product still using the legacy MOHAP labelling template should be re-verified against the current EDE guidance, especially in the presentation of the manufacturer and local authorised representative information.

Insight 2: Electronic package inserts are explicitly accepted, but the access condition must be stated. Subparagraph (g) of Article 6 lists both paper and electronic inserts, which gives electronic form legitimacy. Our recommendation is that high-risk devices used by professional institutions may adopt electronic inserts, but the access path must be stated on the label; for products aimed at individual users or home settings, a paper Arabic insert should remain the primary form, so that the access path does not become a barrier to use.

Insight 3: The label is the hub of cross-stage consistency. The same set of label wording appears in three places: the marketing authorization submission, import customs clearance, and advertising approval. Articles 44 to 47 of the Decree-Law require advertising to be approved by EDE, and Article 46 allows the applicant to choose a validity period of 30 days to 1 year. Our practice is to maintain a single master label text shared by all three stages; any modification starts from the master text and is synchronized outward, otherwise wording differences at the clearance and advertising stages are directly identified as inconsistencies.

4. Practical recommendations

  • Establish the master label text with the Arabic wording as the object of review, using the Chinese or English text only for comparison.
  • Re-verify legacy templates against the current EDE labelling guidance, focusing on the manufacturer and local entity information fields.
  • Compare the inner and outer packaging artwork item by item against the package insert, keeping models, batch number formats, and warnings consistent.
  • Where an electronic insert is used, state the access path on the label and describe the intended users and settings of use.
  • Use the master label text for the registration submission, import clearance, and advertising approval alike, and initiate any modification synchronously.
  • Have the Arabic translation reviewed by personnel with a medical device background to keep terminology and intended use faithful.

5. Verification checklist

  • □ Inner and outer packaging artwork has been provided per the EDE labelling guidance, with complete Arabic information
  • □ The paper or electronic insert format has been decided, and electronic inserts state the access path on the label
  • □ The product generic name and models in the Arabic text match the application form
  • □ Warnings, contraindications, and precautions correspond item by item with the risk management documentation
  • □ The presentation of the manufacturer name, address, and local authorised representative information meets current requirements
  • □ The master label text has been synchronized across the registration, clearance, and advertising stages

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team prepares MOHAP-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail